
Figure 1: 1073 Unredacted Biopharma Alliances Since 1998 with Dev/Reg Milestones Payments, by Stage at Signing*



^{*} Dev/Reg Milestone Payments are for lead program through commercial launch of first indication in all licensed territories



Figure 2: Average Total Dev/Reg Milestones have Increased 2-3 Fold Over the Past Two Decades






Figure 3: Average Total Dev/Reg Milestones for Deals Licensed by 15 Top Pharma have Increased 3-7 Fold Over the Past Two Decades






Figure 4: Total Dev/Reg Milestones for Discovery Stage Alliances by Type of Licensee for 2008+ Deals Vs. 2004-07 Deal Period






Figure 5: Total Dev/Reg Milestones for Preclinical Stage Alliances by Type of Licensee for 2008+ Deals Vs. 2004-07 Deal Period






Figure 6: Total Dev/Reg Milestones for Phase II Stage Alliances by Type of Licensee for 2008+ Deals Vs. 2004-07 Deal Period






Figure 7: Total Dev/Reg Milestones for Phase III Stage Alliances by Type of Licensee for 2008+ Deals Vs. 2004-07 Deal Period






Table 1: Highest and Lowest Biopharma License Payments
Among the 15 Top Pharma Partners

Highest of 15 Top Pharma

Lowest of 15 Top Pharma

	Pharma	Average	Median	Pharma	Average	Median
Deal Size	AZ	\$322M	\$184M	Merck	\$138M	\$64M
Total Dev/Reg *	AZ	\$88M	\$52M	Bayer	\$28M	\$16M
% of Deal	1&1	44%	60%	Novartis	19%	33%
Phase III	181	\$22M	\$5M	Bayer	\$4.5M	\$3M
% of Total *	181	30%	24%	AZ	12%	13%
1 st Approval	AZ	\$37M	\$15M	Bayer	\$8.2M	\$6M
% of Total *	Lilly	51%	41%	Roche	27%	23%

^{*} Total Development & Regulatory Milestones through 1st worldwide approval for 1st indication

Figure 8: Average Total Dev/Reg Milestones for Early Stage University Deals have Increased Significantly over the Past Two Decades






Figure 9: Average Total Dev/Reg Milestones for Early Stage Corporate Deals Still Outpace University Deals by 10-Fold

